Cornerstone taps Chiesi link as it hones hospital focus with anti-infective
This article was originally published in Scrip
Executive Summary
Cornerstone Therapeutics' stock price ticked slightly higher on 8 November, but closed down 0.6% on news that the Cary, North Carolina-based company licensed exclusive US rights to Chiesi Farmaceutici's recently approved Bethkis (tobramycin inhalation solution) to treat chronic pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis.